nach oben

Erschienen in:

12.02.2024 | Original Article

Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis

verfasst von: Vijay S. Are, Mark A. Gromski, Fatih Akisik, Eduardo Vilar-Gomez, Craig Lammert, Marwan Ghabril, Raj Vuppalanchi, Naga Chalasani

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

There are two sub-phenotypes of large-duct primary sclerosing cholangitis (PSC): isolated intrahepatic PSC (IIPSC) and extrahepatic disease with or without intrahepatic (extra/intrahepatic).

Aims

This study examined the differences in outcomes in patients with IIPSC compared to extra/intrahepatic and small-duct PSC.

Methods

Patients with PSC treated at our institution from 1998 to 2019 were investigated. Biochemistries, clinical events, and survival were assessed by chart review and National Death Index. Cox-proportional hazards were used to determine the risk of clinical outcomes based on biliary tract involvement.

Results

Our cohort comprised 442 patients with large-duct PSC (57 had IIPSC, 385 had extra/intrahepatic PSC) and 23 with small-duct PSC. Median follow-up in the IIPSC group was not significantly different from the extra/intrahepatic group [7 vs. 6 years, P = 0.06]. Except for lower age (mean 37.9 vs. 43.0 years, P = 0.045), the IIPSC group was not different from the extra/intrahepatic. The IIPSC group had longer transplant-free survival (log-rank P = 0.001) with a significantly lower risk for liver transplantation (12% vs. 34%, P < 0.001). The IIPSC group had a lower risk of death or transplantation than the extra/intrahepatic PSC group [HR: 0.34, 95% CI: 0.17—0.67, P < 0.001]. No bile duct or gallbladder cancers developed in patients with IIPSC, compared to 24 in the extra/intrahepatic group. The clinical characteristics and outcomes of IIPSC were similar to 23 individuals with small-duct PSC.

Conclusions

Patients with IIPSC have a favorable prognosis similar to small-duct PSC. These data are important for counseling patients and designing therapeutic trials for PSC.

Nur mit Berechtigung zugänglich

Karlsen TH, Folseraas T, Thorburn D et al. Primary sclerosing cholangitis—a comprehensive review. J Hepatol 2017;67:1298–1323.CrossRefPubMed

Chapman MH, Thorburn D, Hirschfield GM et al. British Society of Gastroenterology and UK-PSC guidelines for diagnosing and managing primary sclerosing cholangitis. Gut 2019;68:1356–1378.CrossRefPubMed

Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660–678.CrossRefPubMed

Hirschfield GM, Karlsen TH, Lindor KD et al. Primary sclerosing cholangitis. Lancet 2013;382:1587–1599.CrossRefPubMed

Lindor KD, Kowdley KV, Harrison ME et al. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646–659.CrossRefPubMed

Walmsley M, Leburgue A, Thorburn D et al. FRI-062-Identifying research priorities in primary sclerosing cholangitis: driving clinically meaningful change from the patients’ perspective. J Hepatol 2019;70:e412–e413.CrossRef

Björnsson E, Boberg KM, Cullen S et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731–735.CrossRefPubMedPubMedCentral

Broomé U, Glaumann H, Lindstöm E et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586–589.CrossRefPubMed

Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002;35:1494–1500.CrossRefPubMed

10.

Weismuller TJ, Trivedi PJ, Bergquist A et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975-1984.e8.CrossRefPubMed

11.

Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985;102:581–587.CrossRefPubMed

12.

Goode EC, Clark AB, Mells GF et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology 2019;69:2120–2135.CrossRefPubMed

13.

Fevery J, Van Steenbergen W, Van Pelt J et al. Patients with large-duct primary sclerosing cholangitis and Crohn’s disease have a better outcome than those with ulcerative colitis, or without IBD. Aliment Pharmacol Ther 2016;43:612–620.CrossRefPubMed

14.

Goldberg DS, Levy C, Yimam K et al. Primary sclerosing cholangitis is not rare among blacks in a multicenter North American Consortium. Clin Gastroenterol Hepatol 2018;16:591–593.CrossRefPubMed

15.

Stiehl A, Rudolph G, Klöters-Plachky P et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151–156.CrossRefPubMed

16.

Björnsson E, Lindqvist-Ottosson J, Asztely M et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004;99:502–508.CrossRefPubMed

17.

Mittal S, El-Serag HB, Sada YH et al. Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:124–31.e1.CrossRefPubMed

18.

Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688–694.CrossRefPubMed

19.

Bangarulingam SY, Bjornsson E, Enders F et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010;51:174–180.CrossRefPubMed

20.

Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723–750.CrossRefPubMed

21.

www.cdc.gov/nchs/ndi/index.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fndi.htm. (accessed on January 1, 2023).

22.

Chung BK, Karlsen TH, Folseraas T. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochim Biophys Acta 2018;1864:1390–1400.CrossRef

23.

Lemaigre FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Gastroenterology 2009;137:62–79.CrossRefPubMed

24.

Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008;237:2007–2012.CrossRefPubMedPubMedCentral

25.

Alpini G, Glaser SS, Ueno Y et al. Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol 1998;274:767–775.

26.

LeSage GD, Benedetti A, Glaser S et al. Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. Hepatology 1999;29:307–319.CrossRefPubMed

27.

Liu R, Zhao R, Zhou X et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 2014;60:908–918.CrossRefPubMed

28.

Lozano E, Sanchez-Vicente L, Monte MJ et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res 2014;12:91–100.CrossRefPubMed

29.

Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291–3310.CrossRefPubMed

30.

Yoon JH, Gwak GY, Lee HS et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004;41:808–814.CrossRefPubMed

31.

Yoon JH, Higuchi H, Werneburg NW et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985–993.CrossRefPubMed

32.

McDonald CJ, Overhage JM, Barnes M et al. The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. Health Aff (Millwood) 2005;24:1214–20.CrossRefPubMed

33.

Grigoriadis A, Imeen Ringe K, Bengtsson J et al. Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Rep 2022;4:100595.CrossRefPubMedPubMedCentral

34.

Cazzagon N, El Mouhadi S, Vanderbecq Q et al. Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis. JHEP Rep 2022;4:100577.CrossRefPubMedPubMedCentral

35.

Cristoferi L, Porta M, Bernasconi DP et al. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. Dig Liver Dis. 2023;55(3):373–380.CrossRefPubMed

36.

Eaton JE, Sen A, Hoodeshenas S et al. Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2020;18:1576–1583.CrossRefPubMed

37.

Corpechot C, Gaouar F, El Naggar A et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014;146:970–9 (quiz e15-6).CrossRefPubMed

Titel: Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis
verfasst von: Vijay S. Are
Mark A. Gromski
Fatih Akisik
Eduardo Vilar-Gomez
Craig Lammert
Marwan Ghabril
Raj Vuppalanchi
Naga Chalasani
Publikationsdatum: 12.02.2024
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 4/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-023-08260-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Homeobox Protein BarH-like 1 Promotes Gastric Cancer Progression by Activating Coiled-Coil Domain-Containing Protein 178

Risk Stratification in Primary Sclerosing Cholangitis: Does Size Matter?

Relationship of Age and Gender to Motility Test Results and Symptoms in Patients with Chronic Constipation

Vitamin D Levels as a Potential Modifier of Eosinophilic Esophagitis Severity in Adults

Circular RNA CircSLC22A23 Promotes Gastric Cancer Progression by Activating HNRNPU Expression